Bioporto A/S
BIOPOR.CO operates in the healthcare services and equipment industry, focusing on medical equipment, supplies, and distribution.
Business. BIOPOR.CO is a healthcare services and equipment company operating within the medical equipment, supplies, and distribution industry. The firm generates revenue primarily through the sale of products, including capital equipment and consumables. It is listed on the Nasdaq Copenhagen exchange under the ticker symbol BIOPOR.CO. Specific details regarding operating segments, headquarters location, and geographic revenue mix are not available.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
BIOPOR.CO is a healthcare services and equipment company operating within the medical equipment, supplies, and distribution industry. The firm generates revenue primarily through the sale of products, including capital equipment and consumables. It is listed on the Nasdaq Copenhagen exchange under the ticker symbol BIOPOR.CO. Specific details regarding operating segments, headquarters location, and geographic revenue mix are not available.
BIOPOR.CO's capital structure is characterized by a low debt-to-equity ratio of 0.12, indicating a conservative leverage profile. The company holds substantial cash and equivalents of 54,893,000 DKK, which is significantly higher than its total liabilities of 30,173,000 DKK, resulting in a strong current ratio of 3.25. This liquidity position supports operational flexibility and short-term obligations. However, the company reported negative operating and free cash flows of -77,066,000 DKK and -79,609,000 DKK, respectively, indicating a cash outflow from operations.
Profitability metrics show a challenging performance, with a return on equity of -1.3033 and a return on assets of -0.8813, both significantly below industry norms. The company's operating income of -86,094,000 DKK and net income of -82,117,000 DKK reflect a substantial loss, which is a concern for investors. Gross profit of 30,392,000 DKK is insufficient to cover operating expenses, highlighting inefficiencies in cost management.
The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of diversification increases exposure to sector-specific risks and limits growth opportunities. The absence of capital expenditures suggests a current focus on maintaining operations rather than expanding capacity.
Looking ahead, the company's revenue is projected to increase to 42,000,000 DKK, a 4.2% year-over-year growth, based on analyst estimates. However, the mean EBIT estimate of -63,112,000 DKK indicates continued losses, which could impact long-term sustainability. The company's negative operating cash flow and lack of capital expenditures suggest a need for strategic cost optimization or external financing to support future growth.
Risk factors include a low liquidity risk and a low dilution potential, with no immediate filing-based liquidity or dilution flags detected. The company's low debt levels and strong cash reserves mitigate short-term financial risks. However, the continued negative net income and operating cash flow pose long-term sustainability concerns. No recent filings or transcripts were provided to assess recent events or strategic shifts.
- BIOPOR.CO has a strong liquidity position with a current ratio of 3.25 and significant cash reserves.
- The company is experiencing significant losses, with a return on equity of -1.3033 and a return on assets of -0.8813.
- Revenue is concentrated in a single business segment, increasing exposure to sector-specific risks.
- Analysts project a 4.2% year-over-year revenue growth to 42,000,000 DKK, but continued losses are expected.
- The company has low liquidity and dilution risks, but its negative operating cash flow and lack of capital expenditures suggest a need for strategic cost optimization or external financing.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- BIOPOR.CO Market data — financials · 2026-05-27
- Bioporto A/S Market data — analyst estimates · 2026-05-27